Arkolith/Insider Trading/AVLN/Form 4

Carroll Jill

DirectorAvalyn Pharma Inc. (AVLN) · full profile →Form 4 · filed May 1, 2026
Net Buying
Open-Market Buys
$5.0M
Open-Market Sells
$0
Net Open-Market Flow
$5.0M
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 1, 2026Conversion(C)1.4M——1.4M
May 1, 2026Conversion(C)489K——1.9M
May 1, 2026Buy(P)278K$18.00$5.0M2.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 1, 2026Conversion(C)27.3M——0
May 1, 2026Conversion(C)9.4M——0

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-201894) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML